Cilengitide trifluoroacetate

Name: Cilengitide trifluoroacetate
Brand: Selleck Chemicals
SKU: S7077
Rating: 5 (42 reviews)

For research use only.

Catalog No.S7077 Synonyms: EMD 121974, NSC 707544

42 publications

Cilengitide trifluoroacetate Chemical Structure

CAS No. 199807-35-7

Cilengitide (EMD 121974, NSC 707544) is a potent integrin inhibitor for αvβ3 receptor and αvβ5 receptor with IC50 of 4.1 nM and 79 nM in cell-free assays, respectively; ~10-fold selectivity against gpIIbIIIa. Phase 2.

Selleck's Cilengitide trifluoroacetate has been cited by 42 publications

Nat Genet, 2019, 51(9):1389-1398

PubMed: 31477929 ( click the link to review the publication )

Cell Death Discov, 2020, 6:86

PubMed: 33014430 ( click the link to review the publication )

J Cell Sci, 2020,

PubMed: 32788230 ( click the link to review the publication )

J Cell Mol Med, 2020, 24(2):1460-1473

PubMed: 31828970 ( click the link to review the publication )

J Cell Mol Med, 2020, 24(1):996-1009

PubMed: 31701659 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(18)E6913

PubMed: 32967150 ( click the link to review the publication )

J Biol Chem, 2020, 12 pii: jbc

PubMed: 32280065 ( click the link to review the publication )

Exp Dermatol, 2020, 16

PubMed: 32298492 ( click the link to review the publication )

Blood Adv, 2020, 4(6):1021-1037

PubMed: 32191808 ( click the link to review the publication )

Theranostics, 2019, 9(5):1264-1279

PubMed: 30867829 ( click the link to review the publication )

Nanoscale, 2019, 11(39):18224-18231

PubMed: 31560005 ( click the link to review the publication )

Cell Death Dis, 2019, 10(8):574

PubMed: 31366904 ( click the link to review the publication )

Lab Invest, 2019, 99(11):1636-1649

PubMed: 31249375 ( click the link to review the publication )

Biosci Rep, 2019, 39(8)

PubMed: 31316001 ( click the link to review the publication )

Clin Transl Oncol, 2019,

PubMed: 30632010 ( click the link to review the publication )

Nephron, 2019, 10.1159/000499506

PubMed: 31048591 ( click the link to review the publication )

Phytomedicine, 2019, 61:152859

PubMed: 31039534 ( click the link to review the publication )

Nat Commun, 2018, 9(1):3825

PubMed: 30237420 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(17):4162-4174

PubMed: 29776956 ( click the link to review the publication )

Molecules, 2018, 23(11)E2918

PubMed: 30413113 ( click the link to review the publication )

PLoS One, 2018, 13(10-:e0204930

PubMed: 30281669 ( click the link to review the publication )

Connect Tissue Res, 2018, 59(2):108-119

PubMed: 28301220 ( click the link to review the publication )

J Clin Invest, 2017, 127(10):3624-3639

PubMed: 28846069 ( click the link to review the publication )

Nat Commun, 2017, 8:14348

PubMed: 28128308 ( click the link to review the publication )
J Cell Sci, 2017, 130(18):2971-2983

PubMed: 28754687 ( click the link to review the publication )

Sci Rep, 2017, 7(1):5765

PubMed: 28720870 ( click the link to review the publication )

Radiat Res, 2017, 187(1):79-88

PubMed: 28001908 ( click the link to review the publication )

Int J Clin Exp Pathol, 2017, 10(8):8324-8333

PubMed: 31966683 ( click the link to review the publication )

Cancer Res, 2016, 76(12):3484-95

PubMed: 27216180 ( click the link to review the publication )

Cancer Discov, 2016,

PubMed: 26811325 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(12):2916-2925

PubMed: 27638856 ( click the link to review the publication )

Lab Invest, 2016, 96(11):1178-1188

PubMed: 27668890 ( click the link to review the publication )

Mol Carcinog, 2016, 10.1002/mc.22587

PubMed: 27805285 ( click the link to review the publication )

Mol Biol Cell, 2016, 27(20):3085-3094

PubMed: 27559126 ( click the link to review the publication )

Onco Targets Ther, 2016, 9:1415-23

PubMed: 27042110 ( click the link to review the publication )

Oncotarget, 2016, 7(4):4680-94

PubMed: 26717039 ( click the link to review the publication )

Sci Rep, 2016, 6:35347

PubMed: 27734947 ( click the link to review the publication )

J Clin Invest, 2015, 10.1172/JCI79327

PubMed: 25822023 ( click the link to review the publication )

Biomaterials, 2015, 64:33-44

PubMed: 26115412 ( click the link to review the publication )

Cell Rep, 2015, 13(3):599-609

PubMed: 26456826 ( click the link to review the publication )

Biochim Biophys Acta, 2015, 1853(10 Pt A):2610-20

PubMed: 26193076 ( click the link to review the publication )

Oncotarget, 2015, 6(26):22239-57

PubMed: 26068949 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Integrin Inhibitors

Biological Activity

Description

Targets

αvβ3 receptor ^[1] (Cell-free assay)	αvβ5 receptor ^[2] (Cell-free assay)
4.1 nM	79 nM

In vitro

Cilengitide is a cyclized pentapeptide peptidomimetic designed to compete for the arginine-glycine-aspartic acid (RGD) peptide sequence that regulates integrin-ligand binding. Cilengitide selectively and potently blocks the ligation of theαvβ3 andαvβ5 integrins to provisional matrix proteins such as vitronectin, fibronectin, fibrinogen, von Willebrand factor, osteopontin, and others. ^[1] Cilegitide inhibits angiogenesis in vitro. 10 μM Cilengitide completely inhibits attachment of BAE, BME and HUVE cells on vitronectin and fibronectin. Cilengitide inhibits in vitro angiogenesis of BAE cells on three-dimensional collagen and ﬁbrin gels pretreated with FGF-2(or VEGF-A) with IC50 of 15 μM and 8 μM, 4 μM and 3 μM, respectively. ^[2] Cilengitide blocks proliferation and induces apoptosis of endothelial cells as well as differentiation of human endothelial precursor cells (EPCs). 50 μg/mL Cilengitide completely inhibits the proliferation of human microvascular endothelial cell line HMEC-1 and leads to apoptosis in ~30% cells. ^[3] 1.0 μM Cilengitide treating for 9 days inhibits the proliferation of EPCs by nearly 40%. 1 μM Cilengitide inhibits the differentiation of EPCs by more than 80% at 14 days. ^[4] Cilengitide inhibits adhesion and induces apoptosis of tumor cells. 25 μg/mL Cilengitide causes detachment of DAOY cells (medulloblastoma) and U87MG cells (glioblastoma) from vitronectin and tenascin by more than 60%. 25 μg/mL Cilengitide induces a nearly 50% apoptosis rate of these cells. ^[5]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
G28	NYnwe3JuTnWwY4Tpc44hSXO\|YYm=	NVjUeIY1PTBizsznM41t	NXzre3hWOzBxNkCvNVIxKG2rbh?=		M{X0OYlvcGmkaYTzJJBpd3OyaH;yfYxifGmxbjDv[kBHSUtuIGPyZ{BidmRiQXv0	NVT4dpYzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmxNVQxODVpPkG5NVE1ODB3PD;hQi=>
HMEC-1	M1e4WGZ2dmO2aX;uJGF{e2G7	NIfLOowzOC92MD:2NEDPxGdxbXy=			NXLqS\|ZYcW6qaXLpeJMhTkGNIHHu[EBUemQEoB?=	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTFzNECwOUc,OTlzMUSwNFU9N2F-
G44	NEXKVldCeG:ydH;zbZMhSXO\|YYm=	NYq5bVNqOS93L{WwJO69\y:vbB?=	NWXtWlB7OjRiaB?=		NFq0XmtqdmS3Y3XzJIFxd3C2b4Ppdy=>	NHruOFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUGxOFAxPSd-MUmxNVQxODV:L3G+
G28	NEiwWnZCeG:ydH;zbZMhSXO\|YYm=	NVjZZVFWOS93L{WwJO69\y:vbB?=	MX6yOEBp		MVHpcoR2[2W\|IHHwc5B1d3Orcx?=	Mki1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlzMUSwNFUoRjF7MUG0NFA2RC:jPh?=
G44	Mk\5VJJwdGmoZYLheIlwdiCDc4PhfS=>	NH61N24yNzVxNUCg{txoN22u	MWOyOE81QC95MjDo		MYDpcohq[mm2czDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz	NH\iW3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUGxOFAxPSd-MUmxNVQxODV:L3G+
G28	M3;GTHBzd2yrZnXyZZRqd25iQYPzZZk>	M4rL[VEwPS93MDFOwIcwdWx?	NYewTIVGOjRxNEivO\|IhcA>?		NWfDO3ZmcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	M{XOblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MUG0NFA2Lz5zOUGxOFAxPTxxYU6=
HMEC-1	NEPwb2NCeG:ydH;zbZMhSXO\|YYm=	M163U\|EwPS93MDFOwIcwdWx?	NEnETFUzPCCq		MWXpcoR2[2W\|IHHwc5B1d3Orcx?=	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTFzNECwOUc,OTlzMUSwNFU9N2F-
HMEC-1	NFrQNYpRem:uaX\ldoF1cW:wIFHzd4F6	NV3wc2pOOS93L{WwJO69\y:vbB?=	M4nqS\|I1NzR6L{eyJIg>		M3foOolvcGmkaYTzJJBzd2yrZnXyZZRqd25iaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	NYT4U2FxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmxNVQxODVpPkG5NVE1ODB3PD;hQi=>
HMEC-1	MYfGeY5kfGmxbjDBd5NigQ>?	NILrWocyNzVxNUCg{txoN22u	NFX0eHIzPCCq		M2rzSIlv\HWlZYOgZUBld3OnIHTldIVv\GWwdDDk[ZRi[2ivZX70xsA>	MlL4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTlzMUSwNFUoRjF7MUG0NFA2RC:jPh?=
LNT-229	M{X2O2Z2dmO2aX;uJGF{e2G7	NGfoZmUxNjFxMT:xNEDPxE1?	NYjHN2E4OjRiaB?=		NVXIcWR{cW2yYXnyd{B1cGViYXTo[ZNqd25ib3[gZ4VtdHNidH:geol1em:wZXP0bY4hcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI>	MnrsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl{MkGxO\|EoRjF7MkKxNVcyRC:jPh?=
T98G	MVXGeY5kfGmxbjDBd5NigQ>?	MYKwMlEwOS9zMDFOwG0>	MYiyOEBp		NIPEUm1qdXCjaYLzJJRp\SCjZHjld4lwdiCxZjDj[YxteyC2bzD2bZRzd26nY4TpckBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=>	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTJ{MUG3NUc,OTl{MkGxO\|E9N2F-
LN-18	NH[2[o1HfW6ldHnvckBCe3OjeR?=	MW[wMlEwOS9zMDFOwG0>	NVnSWIY4OjRiaB?=		NULwPGM{cW2yYXnyd{B1cGViYXTo[ZNqd25ib3[gZ4VtdHNidH:geol1em:wZXP0bY4hcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI>	NVjFb4d7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmyNlEyPzFpPkG5NlIyOTdzPD;hQi=>
LN-308	MkTTSpVv[3Srb36gRZN{[Xl?	M3rXTlAvOS9zL{GwJO69VQ>?	M4fCO\|I1KGh?		MULpcZBicXK\|IITo[UBi\Ginc3nvckBw\iClZXzsd{B1dyC4aYTyc45m[3SrbjDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	NH\4e\|I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUKyNVE4OSd-MUmyNlEyPzF:L3G+
U87MG	NVfqWI9JTnWwY4Tpc44hSXO\|YYm=	MortNE4yNzFxMUCg{txO	Ml3UNlQhcA>?		Mn\RbY1x[Wm{czD0bIUh[WSqZYPpc44hd2ZiY3XscJMhfG9idnn0do9v\WO2aX6gbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	MnGxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl{MkGxO\|EoRjF7MkKxNVcyRC:jPh?=
U87	NFfqUWJHfW6ldHnvckBCe3OjeR?=	MWewMVI2KM7:Zz;tUC=>	NID4bocyOiCqwrC=		MmLTbY5lfWOnczDheZRweGijZ4mg[I9{\SCmZYDlcoRmdnSueR?=	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd6OEO0N{c,OjF5OEizOFM9N2F-
U251	MUHGeY5kfGmxbjDBd5NigQ>?	MYCwMVI2KM7:Zz;tUC=>	NG\4WYoyOiCqwrC=		NUHrXFU3cW6mdXPld{BifXSxcHjh[5kh\G:\|ZTDk[ZBmdmSnboTsfS=>	M4nJNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{i4N\|Q{Lz5{MUe4PFM1OzxxYU6=
U87	MXTBdI9xfG:\|aYOgRZN{[Xl?	M1jseVI2KM7:Zz;tUC=>	NIjQT2MzPC92ODDo		MkDhbY5lfWOnczDhdI9xfG:\|aYOgZZQhPDhiaDDzbYdvcW[rY3HueIx6	M4PIWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{i4N\|Q{Lz5{MUe4PFM1OzxxYU6=
U251	NHrONmFCeG:ydH;zbZMhSXO\|YYm=	NEfDe4ozPSEQvHevcWw>	NEjNdFczPC92ODDo		Mk\JbY5lfWOnczDhdI9xfG:\|aYOgZZQhPDhiaDDzbYdvcW[rY3HueIx6	M{TD[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{i4N\|Q{Lz5{MUe4PFM1OzxxYU6=
U87	M4Hqb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUjkZm9QOC1{NTFOwIcwdUx?	MVWwMVQ5KGh?		MlzvbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy	NUKxOYU1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3PFg{PDNpPkKxO\|g5OzR\|PD;hQi=>
U251	NWXTTWQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmfWNE0zPSEQvHevcWw>	M1Hhd\|AuPDhiaB?=		MWfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK=	M13yPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{i4N\|Q{Lz5{MUe4PFM1OzxxYU6=
U251MG	MXzBdI9xfG:\|aYOgRZN{[Xl?	M2P5b\|EhyrWP	NEfCTlc1QCCq		NF;FeGxqdmS3Y3XzJIFxd3C2b4Ppdy=>	MnXKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|NUS4NFcoRjJ\|M{W0PFA4RC:jPh?=
U87MG	M13BZWFxd3C2b4Ppd{BCe3OjeR?=	Mmf6NUDDvU1?	MUi0PEBp		M4HrN4lv\HWlZYOgZZBweHSxc3nz	M2\vflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{W0PFA4Lz5{M{O1OFgxPzxxYU6=
U251MG	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVuwMVI2KM7:TR?=	NV7wdIxTOjRxNEigbC=>		MW\pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK=	MmrYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|NUS4NFcoRjJ\|M{W0PFA4RC:jPh?=
U87MG	M3rQPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXTYdVM6OC1{NTFOwG0>	MlXFNlQwPDhiaB?=		MUjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK=	NX;QUlR[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzOVQ5ODdpPkKzN\|U1QDB5PD;hQi=>
MCF-7	M3HZdmFxd3C2b4Ppd{BCe3OjeR?=	MVOwMVIxKM7:TR?=	NFnNOmE1QCCq		NF23NlZqdmS3Y3XzJIFxd3C2b4Ppdy=>	NH\wOVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG1N\|ExOid-MkSxOVMyODJ:L3G+
T-47D	MofjRZBweHSxc3nzJGF{e2G7	MUmwMVIxKM7:TR?=	MnPuOFghcA>?		NEf0PGJqdmS3Y3XzJIFxd3C2b4Ppdy=>	Mn\wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNUOxNFIoRjJ2MUWzNVAzRC:jPh?=
MCF-7	NGjTfmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYDNXGRFOC1{MDFOwG0>	NHjSc2U6PiCq		NUL5RYFQcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	MlfhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNUOxNFIoRjJ2MUWzNVAzRC:jPh?=
T-47D	MkexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXHwZm1nOC1{MDFOwG0>	MnTqPVYhcA>?		NXTxeJFGcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	NEPCU2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG1N\|ExOid-MkSxOVMyODJ:L3G+
FaDu	NX\a[2dDSXCxcITvd4l{KEG\|c3H5	MYWyOeKhyrWPwrC=	MXW0POKhcMLi		NXjDfnhZcW6mdXPld{BieG:ydH;zbZM>	NHvZ[GQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW1O\|A2Pid-MkS1OVcxPTZ:L3G+
CAL27	MmfSRZBweHSxc3nzJGF{e2G7	NVTW[VVROjYEoNM1UeKh	M1fV[VQ5yqCqwrC=		MYrpcoR2[2W\|IHHwc5B1d3Orcx?=	MlLtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3NUewOVYoRjJ2NUW3NFU3RC:jPh?=
SCC25	NG\NfGNCeG:ydH;zbZMhSXO\|YYm=	MUSyOeKhyrWPwrC=	M{TuUVQ5yqCqwrC=		MmfIbY5lfWOnczDhdI9xfG:\|aYO=	Ml74QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3NUewOVYoRjJ2NUW3NFU3RC:jPh?=
FaDu	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEPkRZQ3NjJ34pETNlAxyqEEtV2=	NFSyWmc4OiCq		NULUenJYemW\|dXz0d{Bud2SncnH0[Uwh\G:\|ZT3k[ZBmdmSnboSg[5Jwf3SqIHnubIljcXSrb36=	NEDoNXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW1O\|A2Pid-MkS1OVcxPTZ:L3G+
CAL27	M{TYS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVq2MlI26oDVMkCwxsDDvU1?	M332W\|czKGh?		Ml7RdoV{fWy2czDtc4RmemG2ZTyg[I9{\S2mZYDlcoRmdnRiZ4Lve5RpKGmwaHnibZRqd25?	NX;qSFlwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1OVcxPTZpPkK0OVU4ODV4PD;hQi=>
SCC25	NYf4TIZkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn;2Ok4zPeLCk{KwNOKhyrWP	MXy3NkBp		NE[xU4Jz\XO3bITzJI1w\GW{YYTlMEBld3OnLXTldIVv\GWwdDDndo94fGhiaX7obYJqfGmxbh?=	NHPlTYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW1O\|A2Pid-MkS1OVcxPTZ:L3G+
H28	MVnD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NGrwPY8yKG6PLUKwNEDPxE1?	MWq3NkBp		MojY[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	NX7vNJJMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1PVUzPzRpPkK0OVk2Ojd2PD;hQi=>
MM05	MnX3R4VtdCCYaXHibYxqfHliQYPzZZk>	M1HH[FEhdk1vMkCwJO69VQ>?	NH;ndlM4OiCq		MX\k[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	M1zndVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUm1Nlc1Lz5{NEW5OVI4PDxxYU6=
MSTO-211H	NXH6e3ZsS2WubDDWbYFjcWyrdImgRZN{[Xl?	NEnpVJgyKG6PLUKwNEDPxE1?	M2X5d\|czKGh?		NHz2XXpl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	NV7I[FZTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1PVUzPzRpPkK0OVk2Ojd2PD;hQi=>
REN	MnyzR4VtdCCYaXHibYxqfHliQYPzZZk>	M{HBXlEhdk1vMkCwJO69VQ>?	MYq3NkBp		NXjENIg5\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDV7NUK3OEc,OjR3OUWyO\|Q9N2F-
LN-308	MlvySpVv[3Srb36gRZN{[Xl?	Moe5NVDjiIoQvH2=	MnL1NlQhcA>?	MWrEUXNQyqB?	M4\yWZJm\HWlZYOgRYhTKHC{b4TlbY4hdGW4ZXzzJIFv\CCGUlWgdoVxd3K2ZYKgZYN1cX[rdIm=	NXHPUZVQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1NFAxPTZpPkK2OVAxODV4PD;hQi=>
HaCaT	MoPXSpVv[3Srb36gRZN{[Xl?	NXP3WIh[OTEkgJpOwI0>	NIjLNI81QCCq	MnTuSG1UV8Li	NGH1OYxz\WS3Y3XzJHRITi4QskNCpI1TVkFiZYjwdoV{e2mxbh?=	M{HneVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NUCwNFU3Lz5{NkWwNFA2PjxxYU6=
S-24	MnfhSpVv[3Srb36gRZN{[Xl?	NVPme25vOS9zMPMAje69dQ>?	MXWyOEBp	M3LoR2ROW00EoB?=	MYny[YR2[2W\|IFTSSUBz\XCxcoTldkBi[3Srdnn0fS=>	M1\LcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NUCwNFU3Lz5{NkWwNFA2PjxxYU6=
ZH-161	Ml;sSpVv[3Srb36gRZN{[Xl?	M3e0XlEwOTEkgJpOwI0>	M3TrPVI1KGh?	Mk[0SG1UV8Li	Mn;vdoVlfWOnczDEVmUhemWyb4L0[ZIh[WO2aY\peJk>	NGLxVZI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkWwNFA2Pid-Mk[1NFAxPTZ:L3G+
LN-308	Mnv5SpVv[3Srb36gRZN{[Xl?	Ml3xNU8yOC9zMEFihKnPxG1?	NXPKcGVYOjRiaB?=	MXzEUXNQyqB?	MlrhdoVlfWOnczDEVmUhemWyb4L0[ZIh[WO2aY\peJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI>	NW\IRohsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1NFAxPTZpPkK2OVAxODV4PD;hQi=>
M21	M{XCcWZ2dmO2aX;uJIF{e2G7		MnLMNUBpeg>?		MnnlRolv\GmwZzDh[oZqdmm2eTD0c{BqdnSnZ4LpckBidHCqYY[vZoV1[TNiaHX0[ZJw\GmvZYKgbY4hcHWvYX6gUVIyKGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[gbY51\We{aX6tcYVlcWG2ZXSgbJVu[W5iTUKxJINmdGxiYXTo[ZNqd25idH:geol1em:wZXP0bY4h[W[2ZYKgNUBpeiCrbjDwdoV{\W6lZTDv[kBOdkOuMjygTWM2OCB;IECuNFAxPCEQvF2u	M4nTRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{WzPFE1Lz5{Nke1N\|gyPDxxYU6=
HEK293T	NIDZWHBHfW6ldHnvckBie3OjeR?=		MlrXNkBpenN?		NF\O[XFDcW6maX7nJIFn\mmwaYT5JJRwKHOxbIXicIUhfHK3bnPheIVlKGi3bXHuJJJm[2:vYnnuZY51KE[lLYTh[4dm\CCjbIDoZXZj\XSjMzDhcoQhcW62ZXfybY5{KHencnWg[ZhxemW\|c3XkJIlvKEiHS{K5N3Qh[2WubIOgZYZ1\XJiMjDodpMh[nliY3;tdIV1cXSrb36gSWxKW0FvbHnr[UBie3OjeTygTWM2OCB;IECuNFAxPTFizszNMi=>	MlrtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyOUWwPVYoRjJ2MEm1NFk3RC:jPh?=
HT-29	MWrGeY5kfGmxbjDhd5NigQ>?		NWTtOo1ROiCqcoO=		Mk[wRY51[WexbnnzeEBi[3Srdnn0fUBifCCrboTl[5JqdiCjbIDoZXZj\XSjNTCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBJXC1{OTDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[2WubDDh[Ihme2mxbjD0c{B3cXS{b37lZ5RqdiCjZoTldkAzKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAxNjF{IN88UU4>	M4r4NVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{WxOVk1Lz5{OEO1NVU6PDxxYU6=
HEK293	NHi2O5RHfW6ldHnvckBie3OjeR?=		NHzqeJczKGi{cx?=		MXrBcpRi\2:waYP0JIFkfGm4aYT5JIF1KGmwdHXndolvKGGucHjhWoJmfGF\|IDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJGhGUzJ7MzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[2WubDDh[Ihme2mxbjD0c{BncWK{aX7v[4VvKGGodHXyJFIhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvOjJizszNMi=>	Ml;3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh\|NUG1PVQoRjJ6M{WxOVk1RC:jPh?=
SKOV3	NHrpSIZHfW6ldHnvckBie3OjeR?=		MUiyJIhzew>?		M3Gw[2FvfGGpb37pd5Qh[WO2aY\peJkh[XRiaX70[YdzcW5iYXzwbIFX[mW2YUPhcJBp[V[kZYThOUApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCVS1;WN{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEBi\Ginc3nvckB1dyCoaXLybY5w\2WwIHHmeIVzKDJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwM{eg{txONg>?	NVjQTpRZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkizOVE2QTRpPkK4N\|UyPTl2PD;hQi=>
U87MG	NHzLXHNHfW6ldHnvckBie3OjeR?=	NHXP[osyODBibl2=	NF\pfZIzPCCqcoO=		NIHT[5FKdmirYnn0bY9vKG:oIHHsdIhiXmKndHGzJIlvfGWpcnnuJIlvKGi3bXHuJHU5P02JIHPlcIx{KGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJJA2OyCjY3P1cZVt[XSrb36gZZQhOTByIH7NJIFnfGW{IEK0JIhzeyCkeTDX[ZN1\XKwIHLsc5QhdWW2aH;k	NV7CZolsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3O\|U{ODNpPkK5O\|c2OzB\|PD;hQi=>
U87MG	NETZRXBHfW6ldHnvckBie3OjeR?=	NUDBN2pPOTByIH7N	NUD5RpQ2OjRiaILz		MYLJcohq[mm2aX;uJI9nKGGucHjhWoJmfGF\|IHnueIVoemmwIHnuJIh2dWGwIGW4O21IKGOnbHzzJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIIC1N{Bi[2O3bYXsZZRqd25iYYSgNVAxKG6PIHHmeIVzKDJ2IHjyd{BqdiCycnXz[Y5k\SCxZjDNSG0zKGmwaHnibZRweiCwdYTsbY4uOyCkeTDX[ZN1\XKwIHLsc5QhdWW2aH;k	NFn5NZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUe3OVMxOyd-Mkm3O\|U{ODN:L3G+
U87MG	MX3GeY5kfGmxbjDhd5NigQ>?	NIPpPVQyODBibl2=	NFL0OZYzPCCqcoO=		NVvvZXNHUW6qaXLpeIlwdiCxZjDhcJBp[V[kZYThN{BqdnSnZ4LpckBqdiCqdX3hckBWQDePRzDj[YxteyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckBxPTNiYXPjeY12dGG2aX;uJIF1KDFyMDDuUUBi\nSncjCyOEBpenNiaX6gdJJme2WwY3Wgc4YhVUSPMjDpcohq[mm2b4KgcpV1dGmwLUOgZY5lKE2GTUSgbY5pcWKrdH;yJHNLNTF5MkK1OVAh[nliV3XzeIVzdiCkbH;0JI1mfGixZB?=	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd5NUOwN{c,Ojl5N{WzNFM9N2F-
U87MG	MYHGeY5kfGmxbjDhd5NigQ>?	NIHae\|IyODBibl2=	NHLYXZE5KGi{cx?=		MWHJcohq[mm2aX;uJI9nKGGucHjhWoJmfGF\|IHnueIVoemmwIHnuJIh2dWGwIGW4O21IKGOnbHzzJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIF3EUVIhdVKQQTDlfJBz\XO\|aX;uJIF1KDFyMDDuUUBi\nSncjC4JIhzeyCrbjDwdoV{\W6lZTDv[kBOTE1{IHnubIljcXSxcjDueZRtcW5vMzDhcoQhVUSPNDDpcohq[mm2b4KgV2ouOTd{MkW1NEBjgSCUVD3QR3IhdWW2aH;k	MnPSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5N{WzNFMoRjJ7N{e1N\|A{RC:jPh?=
U87MG	NHfjfWNHfW6ldHnvckBie3OjeR?=	NXnMOmdVOTByIH7N	MVyyOEBpenN?		NG[xZ\|FKdmirYnn0bY9vKG:oIHHsdIhiXmKndHGzJIlvfGWpcnnuJIlvKGi3bXHuJHU5P02JIHPlcIx{KGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJHBWVUFibWLORUBmgHC{ZYPzbY9vKGG2IEGwNEBvVSCjZoTldkAzPCCqcoOgZpkhWlRvUFPSJI1mfGixZB?=	Mn7qQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5N{WzNFMoRjJ7N{e1N\|A{RC:jPh?=
U87MG	NVPYd2JGTnWwY4Tpc44h[XO\|YYm=	M2nx[\|ExOCCwTR?=	MnPINlQhcHK\|		M3XyeWlvcGmkaYTpc44hd2ZiYXzwbIFX[mW2YUOgbY51\We{aX6gbY4hcHWvYX6gWVg4VUdiY3XscJMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gVHVOSSCvUl7BJIV5eHKnc4Ppc44h[XRiMUCwJI5OKGGodHXyJFI1KGi{czDpckBxemW\|ZX7j[UBw\iCPRF2yJIlvcGmkaYTvdkBvfXSuaX6tN{BjgSCUVD3QR3IhdWW2aH;k	NILOZ4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUe3OVMxOyd-Mkm3O\|U{ODN:L3G+
U87MG	NFjGfZRHfW6ldHnvckBie3OjeR?=	MmTiNVAxKG6P	M3zK[FI1KGi{cx?=		MmPITY5pcWKrdHnvckBw\iCjbIDoZXZj\XSjMzDpcpRm\3KrbjDpckBpfW2jbjDVPFdOTyClZXzsd{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDQWW1CKG2UTlGg[ZhxemW\|c3nvckBifCBzMECgcm0h[W[2ZYKgNlQhcHK\|IHnuJJBz\XOnbnPlJI9nKE2GTUSgbY5pcWKrdH;yJHNLNTF5MkK1OVAh[nliUmStVGNTKG2ndHjv[C=>	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd5NUOwN{c,Ojl5N{WzNFM9N2F-
U87MG	NVHhfFh1TnWwY4Tpc44h[XO\|YYm=	Moq5NVAxKG6P	MVSyOEBpenN?		M3POZWlvcGmkaYTpc44hd2ZiYXzwbIFX[mW2YUOgbY51\We{aX6gbY4hcHWvYX6gWVg4VUdiY3XscJMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gVHVOSSCvUl7BJIV5eHKnc4Ppc44h[XRiMUCwJI5OKGGodHXyJFI1KGi{czDpckBxemW\|ZX7j[UBw\iCPRF2yJIlvcGmkaYTvdkBvfXSuaX6tN{BidmRiTVTNOEBqdmirYnn0c5IhW0pvMUeyNlU2OCCkeTDSWE1RS1JibXX0bI9l	MoHhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5N{WzNFMoRjJ7N{e1N\|A{RC:jPh?=
U87MG	M4PsXmZ2dmO2aX;uJIF{e2G7	MWixNFAhdk1?	M3nKeVI1KGi{cx?=		Mo\BTY5pcWKrdHnvckBw\iCjbIDoZXZj\XSjMzDpcpRm\3KrbjDpckBpfW2jbjDVPFdOTyClZXzsd{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDwNlEhdVKQQTDlfJBz\XO\|aX;uJIF1KDFyMDDuUUBi\nSncjCyOEBpenNiYomgVnQuWEOUIH3leIhw\A>?	NXT4Vmk{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3O\|U{ODNpPkK5O\|c2OzB\|PD;hQi=>
U87MG	MkjyRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?	NFHMR2EyODBibl2=	MUi3NkBpenN?		NHiyTVJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGW4O21IKGOnbHzzJIF1KDFyMDDuUUBi\nSncjC3NkBpenNiaX6gdJJme2WwY3Wgc4YhVUSPMjDpcohq[mm2b4KgcpV1dGmwLUOgZpkhVVSVIHHzd4F6	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd5NUOwN{c,Ojl5N{WzNFM9N2F-
U87MG	NVPsWJZCSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=	M1rzV\|ExOCCwTR?=	MmXoO\|IhcHK\|		M4WxW2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iVUi3UWch[2WubIOgZZQhOTByIH7NJIFnfGW{IEeyJIhzeyCrbjDwdoV{\W6lZTDv[kBOTE1{IHnubIljcXSxcjDueZRtcW5vMzDhcoQhVUSPNDDpcohq[mm2b4KgV2ouOTd{MkW1NEBjgSCPVGOgZZN{[Xl?	NVLYU2k6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3O\|U{ODNpPkK5O\|c2OzB\|PD;hQi=>
U87MG	NFnhPY1E\WyuIHP5Z4xmKGG\|c3H5	NILYfHgyODBibl2=	MmiyNlQhcHK\|		NFrMTXVE\WyuIHP5Z4xmKGG{cnXzeEBqdiCqdX3hckBWQDePRzDj[YxteyCjc4Pld5Nm\CCjczDhZ4N2dXWuYYTpc44h[XRiR{CvS\|EheGijc3WgZZQhOTByIH7NJIFnfGW{IEK0JIhzew>?	NWXKN2RDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3O\|U{ODNpPkK5O\|c2OzB\|PD;hQi=>
U87MG	NFy1SWxCdnSrLXnueoF{cX[nIHHzd4F6	MXOxNEB2VQ>?	NUDm[4Y4OjRiaILz		NGW1ZYdCdnSrLXnueoF{cX[nIHHjeIl3cXS7IHnuJIh2dWGwIGW4O21IKGOnbHzzJIF1KDFyIIXNJIFnfGW{IEK0JIhzeyCkeTD0doFve3enbHygZZN{[Xl?	NX3y[pF[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3O\|U{ODNpPkK5O\|c2OzB\|PD;hQi=>
U87MG	NILoSW9CdnSrLXnueoF{cX[nIHHzd4F6	M2LPfFExKHWP	M1PkR\|I1KGi{cx?=		M4DWVWFvfGlvaX72ZZNqfmViYXP0bZZqfHliaX6gbJVu[W5iVUi3UWch[2WubIOgZZQhOTBidV2gZYZ1\XJiMkSgbJJ{KGmwIIDy[ZNmdmOnIH;mJG1FVTJiaX7obYJqfG:{IH71eIxqdi1\|IHHu[EBOTE12IHnubIljcXSxcjDTTk0yPzJ{NUWwJIJ6KHS{YX7ze4VtdCCjc4PhfS=>	M2DEdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7N{e1N\|A{Lz5{OUe3OVMxOzxxYU6=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pFAK / p-AKT ; PubMed: 19114005 J Exp Clin Cancer Res G28 cells were treated with 50 μg/ml cilengitide for 30, 60 and 120 minutes at 37°C. Cell lysates containing similar amounts of protein were separated by SDS-PAGE, transferred to a nitrocellulose membrane and probed with specific antibodies for detection of β-actin and phosphorylated FAK and Akt. GLI1; PubMed: 31366904 Cell Death Dis Western blottingting showing downregulated GLI1 with Integrin αvβ3 inhibitor Cilengitide and upregulated GLI1 with co-stimulator ligand RGD compared to the blank control in SGC7901 MCAs and BGC823 MCAs.	19114005 31366904
Immunofluorescence	VE-cadherin / β3 integrin ; PubMed: 19212436 PLoS One Confluent HUVEC plated on fibronectin or collagen I were exposed to cilengitide (10 µM each) for the indicated time and double stained for VE-cadherin and β3 integrin. Cilengitide disrupted VE-cadherin staining and promoted appearance of β3 at VE-cadherin-depleted cell-cell borders. Higher magnification of HUVEC cultures demonstrate rare co-localization of VE-cadherin and β3 integrin at cellular junctions upon cilengitide stimulation (arrowheads). Bars: 10 µm.	19212436
Growth inhibition assay	Cell number ; PubMed: 24153102 Radiat Oncol Cell detachment following 1 hr Cilengitide treatment. Cells were treated with cilengitide for 1 hr, washed with PBS, and remaining attached cells were trypsinized and counted. A) T-47D cells showed a strong dose response, with almost complete cell detachment at 20 uM cilengitide treatment. B) MCF-7 cells showed moderate cell detachment similar to C) MDA-MB-231 cells. D) MDA-MB-468 cells showed little to no cell detachment following this short exposure to cilengitide. Figures show Mean ± SEM and represent the average of three experiments. * = ≤ 0.05.	24153102

In vivo

Cilengitide is activity against tumor growth and angiogenesis as single-agent. 100 μg Cilengitide induces a significant decrease in the number of CD 31+ vessels seen in tumors (2/high-power field) compared with control tumors (56/high-power field). 100 μg Cilengitide increases cellular apoptosis in the brain tumors of animals (2.2% apoptotic cells/high-power field) compared with those receiving the inactive peptide (1.7% cells/high-power field). Cilengitide treatment results in prolonged survival of the mice bearing melanoma xenografts M21 compared with control treatment group. (36.5 vs 17.3 days). ^[5] Cilengitide can augment the therapeutic benefit associated with cytotoxic agents including chemotherapy and radiation therapy in tumor models. Cilengitide (250 mg/dose) alone does not alter tumor growth of breast cancer xenografts when compared with untreated mice, but combined modality RIT (CMRIT) using RIT and six doses of Cilengitide (250 mg/dose) increases efficacy of treatment, with the cure rate for mice that receives only RIT increasing from 15 to 53%. CMRIT significantly increases apoptosis of tumor and endothelial cells 5 days, and decreases tumor proliferation. ^[6]

Protocol

Kinase Assay:^[2]	- Collapse Integrin-binding competition assay: Recombinant soluble integrins are immobilized, and peptides, which are serially diluted in Tris-buffered saline (TBS++) (0.1% (w/v) BSA, 150 mM NaCl, 1 mM CaCl₂, 1 mM MgCl₂ 10 μM MnCl₂, 20 mM Tris-HCl; pH 7.4), are added in parallel with biotinylated vitronectin (to 1μg/mL). After a 3-h incubation at 37℃ and washing with Tris–buffered saline, bound ligand is detected by incubation with an antibiotin alkaline phosphatase-conjugated antibody (BioRad) followed by development with p-nitrophenyl phosphatase substrate. The reaction is stopped by the addition of NaOH and the color intensity read at 405 nm.
Cell Research:^[3]	- Collapse Cell lines: Human microvascular endothelial cell line HMEC-1 Concentrations: 1-50 μg/mL Incubation Time: 3 days Method: HMEC-1 (1×10⁴ per well) are seeded on uncoated 48 well plates and incubated in medium containing 4% FCS with Cilengitide. After incubation for 72 hours at 37℃, cells are trypsinized and counted. (Only for Reference)
Animal Research:^[5]	- Collapse Animal Models: Human glioblastoma xenografts U87 MG Dosages: 100μg Administration: Daily i.p. (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	100 mg/mL (142.31 mM)
	Water	8 mg/mL (11.38 mM)
	Ethanol	Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Cilengitide trifluoroacetate SDF

Molecular Weight	702.68
Formula	C₂₉H₄₁F₃N₈O₉
CAS No.	199807-35-7
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	EMD 121974, NSC 707544
Smiles	CC(C)C1C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)N1C)CC2=CC=CC=C2)CC(=O)O)CCCN=C(N)N.C(=O)(C(F)(F)F)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01517776	Terminated	Drug: Cilengitide\|Drug: Temozolomide	Gliomas	Martin-Luther-Universität Halle-Wittenberg\|Merck KGaA Darmstadt Germany	January 2012	Phase 2
NCT01118676	Completed	Drug: cilengitide radiochemotherapy	Locally Advanced Non Small Cell Lung Cancer (NSCLC)*	Institut Claudius Regaud\|Merck KGaA Darmstadt Germany	March 2010	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
The recommend vehicle is 30% propylene glycol, 5% Tween 80, 65% D5W at 30mg/ml, can you let me know if this is a suspension or clear solution?
Answer:
S7077 Cilengitide can be dissolved in 30% propylene glycol/5% Tween 80/65% D5W at 10 mg/ml as a clear solution.
Question 2:
Is Cilengitide a TFA salt?
Answer:
S7077 Cilengitide is actually a TFA salt, and the ratio between Cilengitide and TFA is 1:1.

Choose Your Country or Region

By Signaling Pathways

By product type

Cilengitide trifluoroacetate